Impact Investing

Thuja invests in ventures that are driven by global healthcare challenges, including those related to disease prevention, diagnosis, cure and care. We believe that the objective to improve healthcare is inextricably connected to social impact, as there is the need to ensure quality healthcare that is affordable in the long-term. As such, Thuja’s investment strategy strongly aligns with the United Nations (U.N.) Sustainable Development Goals (SDGs), adopted by all U.N. Member States in 2015. We focus on SDG 3 (Good Health and Well- being) and 9 (Innovation, Industry and Infrastructure), but alongside, we also actively contribute to SDGs 5 and 8. 

Our desire to manage and measure impact is driven by an intrinsic aim to create value for patients and healthcare professionals. This is aligned to our responsibility towards our investors to provide them with a long-term financial return, as we believe that impact is an important determinant for the success of any healthcare venture. Furthermore, we are committed to managing the environmental, social and governance (ESG) factors that are material to the performance of our portfolio companies. We believe that proper ESG management can substantially reduce risk, increase business efficiency and effectiveness, and uncover novel business opportunities.

Thuja underwrites, and is a signatory of, the European Biotech Social Pact and the Principles for Responsible Investment (PRI).

For more information on our approach to impact & sustainable (ESG) investing we refer you to our policy.

SFDR-Related Disclosures
In conformity to the requirements of the regulation (EU) 2019/2088 on sustainability-related disclosures in the financial sector (SFDR), we refer to the SFDR-related disclosures.